Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Further trials sought for MRI (magnetic resonance imaging) contrast agent:

This article was originally published in Clinica

Executive Summary

EPIX Medical and Mallinckrodt will seek US approval to begin Phase III trials of an injectable MRI contrast agent for detecting peripheral vascular disease following successful Phase II studies. The agent, called MS-325, was compared with the current X-ray angiography procedure and had an 82% accuracy in identifying clinically significant stenosis. EPIX, based in Cambridge, Massachusetts, said the agent could provide a minimally invasive way of visualising the peripheral vasculature early on in a patient's assessment and reduce the serious side-effects and complications associated with the highly invasive X-ray angiography procedure.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT083055

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel